2025-12-06 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co Inc. (MRK) based on the data you provided, presented in a clear and concise manner.

**1) Return Rate Comparison:**

*   **Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and manufactures a wide range of prescription medicines, vaccines, and animal health products.
*   **MRK Cumulative Return:** 20.69%
*   **VOO (S&P 500) Cumulative Return:** 100.58%
*   **Divergence:** -78.1 (Relative Divergence: 20.4)
*   **Analysis:** MRK has significantly underperformed the S&P 500 (VOO) over the analyzed period. The divergence of -78.1 indicates a substantial difference in returns. The relative divergence of 20.4 suggests that the current divergence is near the lower end of its historical range (minimum-maximum). In other words, the underperformance isn't the worst it's ever been, but it's still considerable.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 1.0% | 68.5% | -28.0% | 0.0 | 131.3 |
| 2016-2018  | 36.0% | 69.8% | 21.0% | -0.0 | 178.4 |
| 2017-2019  | 40.0% | 69.8% | 18.0% | 0.3 | 212.3 |
| 2018-2020  | 16.0% | 79.6% | -8.0% | 0.3 | 190.9 |
| 2019-2021  | 2.0% | 79.6% | -44.0% | 0.7 | 187.5 |
| 2020-2022  | 15.0% | 79.6% | 16.0% | 0.7 | 271.4 |
| 2021-2023  | 33.0% | 79.6% | 31.0% | 0.3 | 266.7 |
| 2022-2024  | -4.0% | 79.6% | -25.0% | 0.2 | 243.3 |
| 2023-2025  | -29.0% | 71.5% | -94.0% | 1.7 | 250.2 |

*   **CAGR:** Fluctuating, with negative growth in recent periods (2022-2025 and 2023-2025).
*   **MDD (Maximum Drawdown):** High MDD figures indicate significant potential losses during downturns.
*   **Alpha:** Mostly negative recently, especially in the last period (-94.0), showing MRK has failed to beat the market.
*   **Beta:** Generally low, suggesting MRK is less volatile than the market, except for the recent sharp jump to 1.7 during the 2023-2025 period.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** 102.27
*   **Last Market:** Price = 100.16, Previous Close = 100.89, Change = -0.72
*   **5-day SMA:** 103.03
*   **20-day SMA:** 95.49
*   **60-day SMA:** 88.20
*   **Analysis:** The price is currently below the 5-day SMA, but above the 20-day and 60-day SMAs. This suggests a recent short-term pullback after a longer period of upward trend.

**3) Indicators Analysis:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommendation)
*   **RSI:** 72.30 (Overbought territory)
*   **PPO:** 0.4967
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (10 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change:** 1.9 (+) (Short-term increase)
*   **Last Market Change:** price': 100.16, 'previousClose': 100.89, 'change': -0.72 (Reflects a small decline).
*   **Expected Return:** -36.4% (Negative expected return compared to S&P 500 over a long-term investment)
*   **Analysis:** The MRI suggests a medium level of investment risk. The high RSI indicates that the stock may be overbought and could be due for a correction. The PPO being positive suggests that the short-term moving average is above the long-term moving average, indicating a bullish trend. The recent increase in relative divergence indicates a short-term upward trend. However, the significantly negative Expected Return is concerning, suggesting poor future performance compared to the overall market.

**4) Recent News & Significant Events:**

*   **Bullish Analyst Target:** Guggenheim raised its price target to $122 based on Winrevair potential.
*   **Surprise Win, Long Road:** Investor's Business Daily notes a "surprise win," but also indicates challenges remain.
*   **Hedge Fund Pick:** Newser reports MRK is a top hedge fund pick.
*   **Pullback Opportunity:** Trefis suggests the recent pullback is a buying opportunity within an uptrend.
*   **Positive Trading Day:** Yahoo Finance reported a positive trading day.
*   **Analyst Confidence:** MarketBeat reports a slight price increase.
*   **Analysis:** Recent news is a mix of positive and cautious. Analyst upgrades and positive mentions are encouraging, but other articles highlight the potential for remaining challenges.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean 1.97) based on 26 opinions.
*   **Target Price:** Average $106.62, High $139.00, Low $82.00
*   **Recent Rating Changes:** No changes
*   **Analysis:** The analyst consensus indicates a generally positive outlook on the stock, with an average target price slightly above the current price. However, there is a wide range in target prices, indicating uncertainty.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

*   **Trend:** EPS and revenue have been generally increasing over the last four quarters.
*   **Analysis:** Recent earnings data show positive growth in both EPS and revenue, which is a good sign.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|----------------|
| 2025-09-30 | $17.28B     | 77.69%          |
| 2025-06-30 | $15.81B     | 77.50%          |
| 2025-03-31 | $15.53B     | 77.98%          |
| 2024-12-31 | $15.62B     | 75.50%          |
| 2024-09-30 | $16.66B     | 75.51%          |

**Capital and Profitability:**

| Quarter      | Equity      | ROE   |
|--------------|-------------|-------|
| 2025-09-30 | $51.85B     | 11.16% |
| 2025-06-30 | $48.99B     | 9.04%  |
| 2025-03-31 | $48.34B     | 10.51% |
| 2024-12-31 | $46.31B     | 8.08%  |
| 2024-09-30 | $44.50B     | 7.09%  |

*   **Revenue:** Increasing trend in recent quarters.
*   **Profit Margin:** Consistently high and increasing, suggesting strong profitability.
*   **Equity:** Growing, indicating a strengthening balance sheet.
*   **ROE (Return on Equity):** Improving, reflecting better returns on shareholder investments.
*   **Analysis:** The financial data paints a positive picture, with strong and improving revenue, profit margins, equity, and ROE.

**7) Comprehensive Analysis:**

*   **Underperformance vs. S&P 500:** MRK has significantly underperformed the S&P 500 over the period, but the relative divergence is near the lower end of its historical range.
*   **Recent Momentum:** Recent news and short-term indicators suggest a potential uptrend, but the high RSI indicates the stock may be overbought.
*   **Strong Fundamentals:** The company demonstrates solid and improving financial performance.
*   **Analyst Outlook:** The analyst consensus is generally positive.
*   **Negative Expected Return:** Despite the other positive indicators, the negative expected return is a significant concern, suggesting MRK might underperform the market in the long term.
*   **Overall:** MRK presents a mixed picture. It shows positive financial performance and improving earnings, but struggles to beat the S&P 500 and exhibits a negative expected return. Recent analyst upgrades and positive news related to Winrevair may be driving short-term gains, but potential investors should carefully weigh the long-term prospects and historical underperformance.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.